You are viewing: Asia Pacific Plasma Fractionation Market analysis
Part of: Plasma Fractionation Market (Global)

The Asia Pacific Plasma Fractionation Market was valued at $5822.6 Million in 2026 and projected to reach to $8714.7 Million by 2031, representing a compound annual growth rate of 8.4%. The Asia Pacific plasma fractionation market is positioned for sustained growth through 2031, driven by demographic shifts, rising disease prevalence, and expanding healthcare access across the region.

Asia Pacific Plasma Fractionation Market (2026-2031) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Asia Pacific Plasma Fractionation Market Trends and Insights

  • Asia Pacific's market expansion is driven by rising demand for immunoglobulin therapies, increasing prevalence of bleeding disorders, and growing healthcare infrastructure investments across the region.
  • Asia Pacific represents a critical growth frontier, with emerging economies in Southeast Asia and India accelerating adoption of plasma-derived therapies. Asia Pacific's 8.4% compound annual growth rate outpaces the global average of 7.6%, reflecting strong demographic tailwinds and improving patient access to treatment.
  • Asia Pacific's market is characterized by expanding manufacturing capacity, regulatory harmonization efforts, and strategic partnerships between regional and multinational plasma collection organizations.
  • By 2031, Asia Pacific is expected to capture an increasingly significant share of global plasma fractionation demand, supported by aging populations and rising incidence of immunodeficiency conditions across the region..

Key Market Statistics

  • CAGR (2026-2031) 8.4% CAGR
  • Market Size, 2026 ~USD 5822.6 Million
  • Forecast, 2031 ~USD 8714.7 Million
  • Geography Asia Pacific

Asia Pacific Plasma Fractionation Market Overview

Rapid Market Expansion :

Asia Pacific plasma fractionation market is projected to grow from USD 5,822.6 million in 2026 to USD 8,714.7 million by 2031, representing a robust 8.4% CAGR, outpacing the global average of 7.6%.

Rising Immunoglobulin Demand :

Increasing prevalence of immunodeficiency disorders and autoimmune diseases across Asia Pacific is driving significant demand for immunoglobulin therapies, a key plasma fractionation product segment.

Bleeding Disorder Prevalence :

Growing incidence of hemophilia, von Willebrand disease, and other bleeding disorders in Asia Pacific populations is fueling demand for clotting factor concentrates and related plasma-derived therapeutics.

Healthcare Infrastructure Investment :

Substantial government and private sector investments in healthcare infrastructure, diagnostic capabilities, and biopharmaceutical manufacturing across Asia Pacific are creating favorable conditions for market growth.

Asia Pacific Plasma Fractionation Market Dynamics

  • China and Japan lead market development, while emerging economies like India and Southeast Asian nations present significant growth opportunities as healthcare systems modernize and treatment awareness increases. Key growth catalysts include increasing adoption of plasma-derived immunoglobulins for rare diseases, enhanced regulatory frameworks supporting biopharmaceutical development, and growing patient populations requiring long-term plasma fractionation therapies.
  • Strategic partnerships between regional manufacturers and global players are accelerating market penetration and product availability across Asia Pacific..

Market Ecosystem

logo-mobile

PLASMA FRACTIONATION MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES

COMPANY USE CASE DESCRIPTION BENEFITS
company logo
Implemented the Horizon 2 plasma fractionation process at its Kankakee facility to improve immunoglobulin recovery from donated plasma Higher immunoglobulin yield | Improved plasma utilization | Greater production efficiency | Increased supply capacity
company logo
Implemented process improvements through its One Day Batch Release program at plasma-derived therapy manufacturing sites to accelerate batch release Faster batch release | Improved manufacturing efficiency | Shorter lead times | Faster product availability

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

Related Ecosystem

Biotechnology

Top Technologies
  • Reagents
  • Polymerase Chain Reaction (PCR)
  • Stem Cells
  • Assay Kits
  • Flow Cytometers
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.

    Pharmaceuticals

    Top Technologies
    • Bioreactors
    • Analytical Testing
    • Bioanalytical Testing Services
    • Cell Counters
    • Data Management Services
    Top Companies
    • Thermo Fisher Scientific Inc.
    • Merck KGaA
    • SANOFI
    • Pfizer Inc.
    • NOVARTIS

      Key Takeaways

      • Asia Pacific plasma fractionation market valued at USD 5,822.6M in 2026, expanding to USD 8,714.7M by 2031 at 8.4% CAGR
      • Asia Pacific's growth rate of 8.4% exceeds global CAGR of 7.6%, driven by emerging market adoption and healthcare infrastructure development
      • Asia Pacific demand for immunoglobulin and clotting factor therapies is accelerating due to rising disease prevalence and improved diagnostic capabilities
      • Asia Pacific's competitive landscape is intensifying with increased local manufacturing, regulatory approvals, and strategic regional partnerships

      Plasma Fractionation Market Report Scope

      Report Metric Details
      Base Year 2026
      Fastest Growing Segment SCIG (Type)
      Forecast Period 2026-2030
      Growth Rate CAGR of 7.6% from 2026 to 2030
      Largest Segment THERAPEUTICS (Application)
      Market Size Base Year (Billions) ~USD 36.46 (2026)
      Revenue Forecast (Billions) ~USD 48.87 (2030)
      Segments Covered Product, Type, Application, Therapeutic Area, End User

      Asia Pacific Plasma Fractionation Market Report Segmentation

      5 segment dimensions are covered across the global market.

      By Product

      • Albumin
      • Coagulation Factor Concentrates
      • Immunoglobulins
      • Other Plasma Products
      • Protease Inhibitors

      By Type

      • Factor Ix
      • Factor Viii
      • Factor Xiii
      • Fibrinogen Concentrates
      • Ivig
      • Other Coagulation
      • Other Coagulation Factor Concentrates
      • Other Immunoglobulins
      • Prothrombin Complex Concentrates
      • Prothrombin Factor Concentrates
      • Scig
      • Von Willebrand Factor

      By Application

      • Academics & Preclinical Research
      • Therapeutics

      By Therapeutic Area

      • Critical Care
      • Hemato-Oncology
      • Hematology
      • Immunology
      • Neurology
      • Other Therapeutic Areas
      • Pulmonology
      • Rheumatology

      By End User

      • Home Care Settings & Infusion Centers
      • Hospitals & Specialty Clinics
      • Other End Users

      Target Audience

      • Pharmaceutical & Biopharmaceutical Companies : Plasma fractionation manufacturers and immunoglobulin producers need Asia Pacific market intelligence to identify expansion opportunities, assess competitive threats, and optimize product portfolios for regional demand.
      • Healthcare Investors & Private Equity : Investment firms evaluating opportunities in Asia Pacific healthcare and biopharmaceuticals require detailed market sizing, growth forecasts, and regional dynamics to support investment thesis development and due diligence.
      • Hospital & Healthcare Systems : Hospital networks and healthcare providers across Asia Pacific need market data to inform procurement strategies, budget planning for plasma-derived therapeutics, and understanding of supply chain dynamics.
      • Regulatory & Government Bodies : Healthcare regulators and government agencies in Asia Pacific countries utilize market research to inform policy decisions, healthcare infrastructure planning, and therapeutic access initiatives for plasma fractionation products.
      • Market Research & Consulting Firms : Research organizations and management consultants require comprehensive Asia Pacific plasma fractionation data to support client advisory services, competitive analysis, and strategic planning engagements.

      Asia Pacific vs. other regions

      HowAsia Pacific compares to the other 3 regional blocs covered in this market.

      North America
      ~USD 28658.5 Million · 7.8% wtd CAGR ·
      Europe
      ~USD 11986.7 Million · 7.3% wtd CAGR ·
      Latin America
      ~USD 2826.1 Million · 6.8% wtd CAGR ·
      Middle East
      ~USD 988.6 Million · 4.4% wtd CAGR ·

      Countries within Asia Pacific - compare and drill down

      Country2025 size (native)
      ChinaUSD 5216.6 Million
      JapanUSD 1328.1 Million
      IndiaUSD 432.2 Million
      South KoreaUSD 310.2 Million
      AustraliaUSD 1055.5 Million
      VietnamUSD 49.5 Million
      MalaysiaUSD 61.7 Million
      IndonesiaUSD 99.3 Million

      Country market size visualization

      China
      USD 5216.6 Million
      Japan
      USD 1328.1 Million
      India
      USD 432.2 Million
      South Korea
      USD 310.2 Million
      Australia
      USD 1055.5 Million
      Vietnam
      USD 49.5 Million
      Malaysia
      USD 61.7 Million
      Indonesia
      USD 99.3 Million

      Reasons to Buy this Report

      • Regional Market Segmentation : Gain detailed insights into Asia Pacific's plasma fractionation market dynamics, including country-level analysis of China, Japan, India, Australia, and South Korea with specific market valuations and growth trajectories.
      • Competitive Landscape Intelligence : Understand regional competitive positioning, market share distribution among plasma fractionation manufacturers, and emerging players capturing growth opportunities across Asia Pacific healthcare systems.
      • Growth Driver Analysis : Identify and quantify key growth drivers specific to Asia Pacific including rising immunoglobulin demand, bleeding disorder prevalence, healthcare infrastructure investments, and regulatory environment changes.
      • Investment & Expansion Strategy : Develop informed market entry and expansion strategies for Asia Pacific with data-driven insights on high-growth countries, emerging market segments, and partnership opportunities with regional stakeholders.
      • Forecast Accuracy : Access reliable 5-year forecasts (2026-2031) for Asia Pacific plasma fractionation market with 8.4% CAGR projections, enabling confident business planning and resource allocation decisions.

      Frequently asked questions

      What is the projected market size for plasma fractionation in Asia Pacific by 2031?

      Asia Pacific's plasma fractionation market is projected to reach USD 8,714.7 million by 2031, growing from USD 5,822.6 million in 2026.

      What is the CAGR for Asia Pacific plasma fractionation market?

      Asia Pacific's plasma fractionation market is expected to grow at a compound annual growth rate of 8.4% between 2026 and 2031.

      What factors are driving growth in Asia Pacific's plasma fractionation market?

      Asia Pacific growth is driven by increasing prevalence of bleeding disorders, rising demand for immunoglobulin therapies, expanding healthcare infrastructure, and improving patient access to plasma-derived treatments.

      How does Asia Pacific's growth compare to the global plasma fractionation market?

      Asia Pacific's 8.4% CAGR outpaces the global market CAGR of 7.6%, positioning the region as a high-growth segment within the global plasma fractionation industry.

      Which countries in Asia Pacific are driving plasma fractionation market expansion?

      Emerging economies including India, Southeast Asian nations, and China are primary growth drivers in Asia Pacific, supported by rising healthcare spending and improving regulatory frameworks.

      RESEARCH METHODOLOGY

      This research study extensively used secondary sources, directories, and databases to identify and collect valuable information for analyzing the global plasma fractionation market. In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and to assess the market's growth prospects. The global market size estimated through secondary research was triangulated with inputs from primary research to determine the final market size..

      Secondary Research

      The secondary sources for this research study include publications from government sources, such as FDA/CBER, EMA, WHO, and national health and regulatory authorities; industry associations, such as the Plasma Protein Therapeutics Association (PPTA), the International Plasma and Fractionation Association (IPFA), and AABB; and commercial databases, such as Bloomberg Business, D&B, Factiva, and relevant trade databases. Additional sources include white papers, annual reports, company house documents, investor presentations, scientific and clinical publications, regulatory filings, patent databases, and product and clinical trial databases. Secondary research was used to identify and collect information for the extensive, technical, market-oriented, and commercial study of the plasma fractionation market. It was also used to obtain important information about key players, market classification, segmentation according to industry trends, the bottom-up approach, and key developments from market and technology perspectives. Secondary data was also used to assess plasma collection capacity, fractionation and manufacturing infrastructure, product portfolios, regulatory frameworks, trade patterns, clinical applications, and regional market trends. These sources were also used to gather key information about major players, market classification, and segmentation based on industry trends, regional/country-level markets, market developments, and technological perspectives.

      Primary Research

      In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and to assess the market’s prospects. Primary sources from both the supply and demand sides of the market were interviewed to gather qualitative and quantitative information.

      Plasma Fractionation Market
 Size, and Share

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      The top-down and bottom-up approaches were used to estimate & validate the total size of the plasma fractionation market. These methods were also used extensively to estimate the size of various market segments.

      Plasma Fractionation Market : Top-Down and Bottom-Up Approach

      Plasma Fractionation Market Top Down and Bottom Up Approach

      Data Triangulation

      After evaluating the overall market size through the market size estimation process, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were used, whenever applicable, to complete the overall market engineering process and obtain precise statistics for all segments and subsegments. The data was triangulated by analyzing various factors and trends from both the demand and supply sides.

      Market Definition

      Plasma-derived therapies are medical treatments based on human plasma. Plasma is the largest component of human blood and contains water, salts, enzymes, antibodies, and other proteins. Before it can be used in medical therapies, it undergoes a fractionation process in which the relevant proteins are separated. Plasma-derived therapies are used to treat a wide range of (rare) diseases, from bleeding disorders and inhibitor deficiencies to primary and secondary immunodeficiencies.

      Key Stakeholders

      • Plasma Fractionation Product Manufacturers and Distributors
      • Pharmaceutical and Biotechnology Companies
      • Healthcare Service Providers (including Hospitals and Clinics)
      • Research and Development (R&D) companies
      • Academic Institutes
      • Government Associations
      • Market Research and Consulting Firms
      • Venture Capitalists and Investors

      Report Objectives

      • To define, describe, and forecast the plasma fractionation market based on product, application, therapeutic area, end user, and region
      • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
      • To strategically analyze micromarkets concerning individual growth trends, prospects, and contributions to the overall plasma fractionation market
      • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
      • To forecast the size of the market segments concerning six main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
      • To strategically profile the key players in the plasma fractionation market and comprehensively analyze their core competencies and market rankings
      • To track and analyze competitive developments such as product launches, acquisitions, expansions, agreements, partnerships, and collaborations in the plasma fractionation market
      • To benchmark players within the plasma fractionation market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and product/service strategy

      Available customizations:

      With the given market data, MarketsandMarkets offers customizations per the company’s specific needs. The following customization options are available for this report:

      Product Analysis

      • Further breakdown of the Rest of Europe Plasma Fractionation Market, by country
      • Further breakdown of the Rest of Asia Pacific Plasma Fractionation Market, by country
      • Further breakdown of the Rest of Latin America Plasma Fractionation Market, by country
      • Further breakdown of the Rest of Middle East Plasma Fractionation Market, by country

      Company Information

      • Detailed analysis and profiling of additional market players (up to five)

      Get the Full Plasma Fractionation Market Report

      Full forecast, segment splits, and company analysis for all Plasma Fractionation Market.

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      DMCA.com Protection Status